Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04544007 · ClinicalTrials.gov registry record · Phase 2
A Phase II Trial of Poly-ICLC for Low-Grade Gliomas
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT04544007 is a Phase 2 study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 3 participants.
The verdict
NCT04544007, a Phase 2 study, was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a phase II, prospective, longitudinal, multi-center trial of poly-ICLC (Hiltonol ®) treatment for progressive low-grade gliomas in pediatric patients with NF1. The primary objective is to evaluate the efficacy of poly-ICLC in pediatric NF1 patients with progressive low-grade glioma (LGG) as measured by objective tumor response rate (CR+PR) within the first 48 weeks (12 cycles) of therapy. There will also be secondary and exploratory objectives listed in the detailed description below.
Interventions
- DRUG Poly ICLC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2022-02-08 |
| Est. Completion | 2024-11-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04544007
The ClinicalTrials.gov registry entry for NCT04544007 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Poly ICLC is the first listed.
NCT04544007 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04544007 about?
NCT04544007 is a clinical study titled "A Phase II Trial of Poly-ICLC for Low-Grade Gliomas". This is a phase II, prospective, longitudinal, multi-center trial of poly-ICLC (Hiltonol ®) treatment for progressive low-grade gliomas in pediatric patients with NF1. The primary objective is to evaluate the efficacy of poly-ICLC in pediatric NF1 patients with progressive low-grade glioma (LGG) as ...
What is the current status of trial NCT04544007?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2022-02-08. Estimated completion is 2024-11-15.
What interventions are being tested in trial NCT04544007?
The interventions under investigation include: Poly ICLC (DRUG).
Who is sponsoring clinical trial NCT04544007?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.